
    
      The primary objective of the protocol is to evaluate the toxicity and tolerability of this
      mixed chimerism matched unrelated donor allogeneic transplant approach for patients with
      multiple myeloma. Response, toxicity, survival and graft-versus-host disease will be
      evaluated.
    
  